ETON
Eton Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ETON Profile
Eton Pharmaceuticals, Inc.
An innovative pharmaceutical company that having a product portfolio in Orphan Drugs, Hospital Products, and Royalty Products
21925 W. Field Parkway, Suite 235, Deer Park, IL 60010-7278
--
Eton Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on April 27, 2017. The Company is an innovative pharmaceutical company focused on developing, acquiring and commercializing innovative products to meet the unmet needs of patients with rare diseases. The company currently has four commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenal insufficiency, glutamate for the treatment of hyperammonemia caused by deficiency of N-acetylglutamate synthase; betaine anhydrous for the treatment of homocysteinuria; nitticinone for the treatment of type 1 hereditary tyrosinemia, and three other product candidates are in late-stage development. The company is developing dehydrated alcohol injection, which has obtained orphan drug status for the treatment of methanol poisoning, ZENEO hydrocortisone auto-injector and ET-400 for the treatment of adrenal crisis.